Meeting
2013 ASCO Annual Meeting
Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): Subgroup analysis of TURANDOT.
Authors
Moshe J. Inbar
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Moshe J. Inbar , Istvan Lang , Zsuzsanna Kahan , Richard Greil , Semir Beslija , Salomon M. Stemmer , Bella Kaufman , Silke Ahlers , Thomas Brodowicz , Christoph Zielinski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT00600340
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1040)
DOI
10.1200/jco.2013.31.15_suppl.1040
Abstract #
1040
Poster Bd #
18G
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).
First Author: Denise A. Yardley
Poster
2023 ASCO Annual Meeting
FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.
First Author: Shao Zhimin
Poster
2018 ASCO Annual Meeting
An open label, single arm, prospective phase II study to evaluate the efficacy and safety of bevacizumab with gemcitabine and carboplatin as first-line treatment for metastatic triple negative breast cancer patients.
First Author: Sudeep Gupta
Poster
2014 ASCO Annual Meeting
tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).
First Author: Denise A. Yardley